No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
INKT MiNK Therapeutics
- 0.920
- -0.046-4.77%
Close Jun 14 16:00 ET
- 0.905
- -0.014-1.55%
Post 19:54 ET
31.94MMarket Cap-1558P/E (TTM)
0.980High0.902Low55.88KVolume0.970Open0.966Pre Close52.90KTurnover1.05%Turnover RatioLossP/E (Static)34.73MShares3.34052wk High-1.57P/B4.90MFloat Cap0.75052wk Low--Dividend TTM5.33MShs Float22.155Historical High--Div YieldTTM8.08%Amplitude0.750Historical Low0.946Avg Price1Lot Size
Full Hours
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
MiNK Therapeutics Announces Virtual Annual Shareholders Meeting
PDF Version NEW YORK, June 05, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commerc
MiNK Presents AgenT-797 Clinical Activity in Immune-Compromised Transplant Patient With Severe ARDS at ATS Annual Meeting
PDF Version NEW YORK, May 22, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commerci
MiNK Therapeutics Poised for Growth With Strong Trial Enrollment and New Investments: A Buy Rating From Jack Allen
MiNK Therapeutics Inc (INKT) Q1 2024 Earnings Call Transcript Highlights: Strategic Reductions ...
Earnings Call Summary | MiNK Therapeutics(INKT.US) Q1 2024 Earnings Conference
The following is a summary of the MiNK Therapeutics, Inc. (INKT) Q1 2024 Earnings Call Transcript:Financial Performance:MiNK Therapeutics managed to reduce its operating expense by over 45% owing to e
Express News | MiNK Therapeutics Shares Are Trading Lower. The Company Reported Q1 Financial Results
Comments
$MiNK Therapeutics(INKT.US$ NEW YORK, May 22, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ:INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced presentation of clinical data on agenT-797 in a complex case of severe acute respiratory distress (ARDS) at ...
MiNK Therapeutics Secures $5.8 Million in Private Placement to Fuel Cancer Therapy Development.
MiNK Therapeutics, Inc. (NASDAQ: INKT), a company in the biopharmaceutical sector, has announced an essential milestone in its quest to revolutionize cancer treatment. With a focus on developing allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies for cancer and other immune-mediated diseases, MiNK has...
MiNK Therapeutics, Inc. (NASDAQ: INKT), a company in the biopharmaceutical sector, has announced an essential milestone in its quest to revolutionize cancer treatment. With a focus on developing allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies for cancer and other immune-mediated diseases, MiNK has...
$MiNK Therapeutics(INKT.US$ Benzinga· 2 mins
MiNK Therapeutics Shares Are Trading Higher After the Company Announced Plans to Sell Securities in a Private Placement Financing for $5.8 Million. The Financing Is Earmarked for Accelerating Its MiNK-215 Clinical Trials
MiNK Therapeutics Shares Are Trading Higher After the Company Announced Plans to Sell Securities in a Private Placement Financing for $5.8 Million. The Financing Is Earmarked for Accelerating Its MiNK-215 Clinical Trials
$MiNK Therapeutics(INKT.US$
NEWS
MiNK Therapeutics Announces $5.8 Million Private Placement and Appointment of Board Observer
NEWS
MiNK Therapeutics Announces $5.8 Million Private Placement and Appointment of Board Observer
2
4
$MiNK Therapeutics(INKT.US$
CEO bought a lot
CEO bought a lot
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg